Bullish Stocks Upgraded By Analysts: $CRL $CPSI $BBCP

The Market Signal was created as a platform to help investors, if you own (NYSE:CRL), (NASDAQ:CPSI) or (NASDAQ:BBCP) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/Free-Report/NOW
(Click link above or copy, paste and hit enter in your browser for your report)

Charles River Laboratories To Acquire Cellero for $38 million

https://themarketsignal.com//Free-Report/CRL

(Click link above or copy, paste and hit enter in your browser for your report)

Charles River Laboratories (NYSE:CRL) has been upgraded by Oppenheimer to 'Outperform' from 'Perform,' and has the current target price of $235.44 While the current stock price is $214.96. The company expanded its services to cell therapy last year with a $380 million HemaCare acquisition. Fresh off this acquisition the company entered a definitive agreement last month for the acquisition of Cellero as it enhances its position in the cell and gene therapy market. The company will acquire Cellero for around $38 million.

Despite the pandemic, the company saw its revenue in Q2 edge up by 3.8% to $682.6 million from $657 in Q2 2019. Around 3.2% of the growth was from acquisitions and 0.8% from the foreign exchange with organic revenue growing 1.4%.

Computer Program and Systems Approves $30 Million Share Repurchase Program

https://themarketsignal.com/Free-Report/CPSI

(Click link above or copy, paste and hit enter in your browser for your report)

Another stock upgraded by Oppenheimer to 'Outperform' from 'Perform is Computer Program and System Inc. (NASDAQ:CPSI) with a current target price of $28.89. Currently, the stock is trading at $29.60. The company has announced that its board has approved a share repurchase program under which CPSI will buy around $30 million in the aggregate amount of outstanding common stock through privately negotiated deals, open market purchases, and in compliance with Rule 10b-18 under the 1934 SEC Act.

The shares will be bought from time to time over two years depending on market conditions. Following the approval of the value-enhancing share repurchase program, the company's board suspended indefinitely all quarterly dividends.

Brundage Bone Concrete Pmpg Reports Q3 2020 results

https://themarketsignal.com/Free-Report/BBCP

(Click link above or copy, paste and hit enter in your browser for your report)
Brundage Bone Concrete Pmpg Hldg Inc. (NASDAQ:BBCP) which currently trades at $3.68 has been upgraded by Oppenheimer to 'Outperform' from 'Perform,' with a current target price of $4.55. The company has reported its fiscal Q3 2020 results in which revenue was $77.1 million compared to $78.7 million in Q3 2019. Net income attributable to shareholders was $2.5 million or $0.04 per share compared to $2.3 million or $0.05 per share a year ago.

Adjusted EBITDA came in at $30 million compared to $30.6 million in Q3 2019 with the adjusted EBITDA margin constant at 38.9%. At the end of the quarter, the company had liquidity of $43.5 million with net debt of $395.3 million.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

comtex tracking

COMTEX_371124885/2705/2020-09-11T07:34:38

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.